peptides6155.com › Info › Identity And Pharmacological Mechanism — Explained

Identity And Pharmacological Mechanism — Explained

By Editorial Desk · published 2026-06-09 · last reviewed 2026-06-23 · Info

If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-06-23. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Pharmacological Mechanism

Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.

The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.

Mechanism and Detection

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.

Cardarine at a glance

PropertyValueNotes
Chemical classSynthetic PPARδ agonistNot a steroid or a selective androgen receptor modulator.
Common synonymsCardarine, GW501516, GW-501516, endurobolNames vary by supplier and literature source.
AppearanceWhite to off-white powderConsistent with many small-molecule research chemicals.
SolubilityLow in water; soluble in DMSO and ethanolOften prepared in organic solvent for laboratory work.
Primary targetPPARδ (NR1C2)Nuclear receptor involved in lipid and energy metabolism.

Identity and Regulatory Status

Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Related pages on this site

Regulation and Detection

Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.

Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.

Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.

Mechanism and Safety Research

GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.

Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.

Reference notes

The A form occurs under non-physiological conditions in partly dehydrated samples of DNA, while in the cell it may be produced in hybrid pairings of DNA and RNA strands, and in enzyme-DNA complexes. Segments of DNA where the bases have been chemically modified by methylation may undergo a larger change in conformation and adopt the Z form. Here, the strands turn about the helical axis in a left-handed spiral, the opposite of the more common B form. These unusual structures can be recognized by specific Z-DNA binding proteins and may be involved in the regulation of transcription.

=== Diagnostic tests === Once monoclonal antibodies for a given substance have been produced, they can be used to detect the presence of this substance. Proteins can be detected using the Western blot and immuno dot blot tests. In immunohistochemistry, monoclonal antibodies can be used to detect antigens in fixed tissue sections, and similarly, immunofluorescence can be used to detect a substance in either frozen tissue section or live cells.

== Further reading == (in French) Bernardi AC (1858). Monographie du genre Conus (in French). Berschauer D. (2010). Technology and the Fall of the Mono-Generic Family The Cone Collector 15: pp. 51–54 Bruguière JG (1792). "Histoire Naturelle des Vers". Encyclopédie Méthodique. Vol. 1. Paris: Panckoucke. pp. 345–757. Clench WJ (1942). "The Genus Conus in the Western Atlantic". Johnsonia. 1 (6): 1–40. Coltro Jr J (2004). "New species of Conidae from northeastern Brazil (Mollusca: Gastropoda)". Strombus. 11: 1–16. Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, Lewin NA, Nelson LS, eds. (28 March 2006). Goldfrank's Toxicologic Emergencies (8th ed.). New York: McGraw-Hill. ISBN 978-0-07-143763-9. Franklin JB, Subramanian KA, Fernando SA, Krishnan KS (2009). "Diversity and Distribution of Conidae from the Tamil Nadu Coast of India (Mollusca: Caenogastropoda: Conidae)". Zootaxa. 2250: 1–63. doi:10.11646/zootaxa.2250.1.1. Franklin JB, Fernando SA, Chalke BA, Krishnan KS (2007). "Radular morphology of Conus (Gastropoda: Caenogastropoda: Conidae) from India" (PDF). Molluscan Research. 27 (3): 111–122. doi:10.11646/mr.27.3.1. García EF (2006). "Conus sauros, a new Conus species (Gastropoda: Conidae) from the Gulf of Mexico". Novapex. 7: 71–76. Gmelin, J. F. 1791. Systema naturae per regna tria naturae. Editio decima tertia. Systema Naturae, 13th ed., vol. 1(6): 3021–3910. Lipsiae. Kiener LC (1845). "Genre Cone. (Conus, Lin.).". Spécies Général et Iconographie des Coquilles Vivantes. Vol. 2. pp. 1–111. Kohn A. A. (1992). "Chronological Taxonomy of Conus, 1758-1840".

A large-scale study was conducted in Mexico. The study compared 793,487 adults vaccinated with different vaccines with 4,792,338 unvaccinated adults between 24 December 2020, and 27 September 2021.The results were as follows:

== Capital crimes == In addition to the Penal Code, there are four Acts of Parliament that prescribe death as punishment for offences. According to the Think Centre, a Singaporean civil rights group, 70% of hangings are for drug-related offences. All eight hangings in 2017 were for drug-related offences that year, and 11 of 13 hangings in 2018 were also for drug-related offences.

Sources: en.wikipedia.org

Notes from published material

=== Research === During his long career at WSLH, Inhorn pursued many different lines of medical research and public health intervention. In 1960, WSLH was involved in a large community program to promote the new Pap smear test for detecting the early stages of cervical cancer. Inhorn devoted many hours to training personnel in family planning clinics on how to carefully make and screen the Pap smear, both of which are essential to its success. During this time, Inhorn also became active in the American Society of Cytopathology. He chaired its committees to develop best practices in laboratory operation, and he eventually became president of ASC, later receiving the Papanicolaou Award for his contributions to the field of cytopathology. In addition, by 1960, new techniques in the field of cytogenetics permitted the study of infants and children with congenital malformations. Inhorn provided the laboratory component that permitted pediatricians from the UW Medical Center to study a large number of affected children. In particular, Down syndrome had been identified as having three chromosome 21s, instead of two. The Cytogenetics Lab at WSLH identified another trisomy (trisomy 13), an important discovery contributing to the genomic revolution that followed.

==== Non-competitive ==== A non-competitive inhibitor binds to a site other than where the substrate binds. The substrate still binds with its usual affinity and hence Km remains the same. However the inhibitor reduces the catalytic efficiency of the enzyme so that Vmax is reduced. In contrast to competitive inhibition, non-competitive inhibition cannot be overcome with high substrate concentration.

Stromelysin-1 also known as matrix metalloproteinase-3 (MMP-3) is an enzyme that in humans is encoded by the MMP3 gene. The MMP3 gene is part of a cluster of MMP genes which localize to chromosome 11q22.3. MMP-3 has an estimated molecular weight of 54 kDa.

== Biological functions == Besides being a structural receptor, integrin α2β1 is a signaling receptor which receives signals from the extracellular medium to the intracellular part of the cell. Integrin α2β1 controls the process of cell migration. The process of cell migration takes place during embryogenesis, wound healing, and tissue remodeling. In these cases, the cells have to move through the extracellular matrix in a controlled manner. The interaction between α2β1 integrin and collagen functions in the migration of cells by creating focal adhesion that are specialized protein structures which assist in connecting actin filament of the cytoskeleton to the extracellular matrix. The receptor has a role in intracellular signaling pathway that regulate cell proliferation, cellular differentiation, and survival. It activates the signal molecules such as FAK, Src family of kinases, phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK). All these processes contribute to gene expression, reorganization of the cytoskeleton, and response to environmental cues. These functions allow α2β1 in the regulation of normal tissue homeostasis and repair and adaptation of the cells to the changes in the environment provided by the extracellular matrix. Integrin α2β1 is involved in the process of hemostasis as the integrin facilitates the adhesion of platelets to exposed collagen at sites of vascular damage. The receptor is also important to the immune system functioning.

(For a renovation that began in 1999, the RATP, the Paris transportation authority, restored the entrances to two slightly different shades: at sites with a lot of vegetation, vert wagon ('train-car green'), the dark green used for Parisian public works at the turn of the 20th century, and at fully urban sites, a slightly bluer shade, vert allemand ('German green').) He designed standardized components, including railing cartouches incorporating the letter "M" and signs in his own distinctive lettering reading "Métropolitain" or, at narrow entrances, "Métro"; later the use of the lettering was extended to a holder for a system map and for advertising (porte-plan) with the station name above. In addition to speed (the first set of entrances were installed within six months of their design) and relatively low cost in manufacture and adaptation to different sizes and locations of entrances, all of this gave the system a stylistic identity.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.

How does cardarine interact with the body?

It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.

Is cardarine found naturally?

No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.

How does cardarine work in the body?

It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.

Network